Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual ...

Low-Dose Total Skin Electron Beam Radiotherapy in Stage IB-IIB Mycosis Fungoides: Results From the Prospective S-MISR Study Eftilagimod alpha (efti), an antigen-presenting cell (APC) activator, may ...

A newly discovered cancer trick that weakens immunotherapy may be stopped by everyday statins.

Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small cell lung cancer will benefit from immunotherapy.

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small cell lung cancer will benefit from immunotherapy.

Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua® through the country’s National Health Insurance coverage.

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small-cell lung cancer will benefit from immunotherapy.